Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Congenital Hyperinsulinism Treatment Market

Congenital Hyperinsulinism Treatment Market Trends

Report ID: GMI6333
Published Date: Jul 2023
Report Format: PDF

Download Free Sample

Congenital Hyperinsulinism Treatment Market Trends

The increasing prevalence of congenital hyperinsulinism (CHI) worldwide is anticipated to boost the market growth. For instance, according to the Orphanet Journal of Rare Diseases report, congenital hyperinsulinism has an estimated global prevalence of 1/50,000. Similarly, as per National Institute of Health (NIH) report, congenital hyperinsulinism (HI) is the most frequent cause of severe, persistent hypoglycemia in new-born babies and children. In most countries, hyperinsulinism occurs in approximately 1/25,000 to 1/50,000 births. About 60% of babies with hyperinsulinism develop hypoglycemia during the first month of life. Thus, the increasing number of congenital hyperinsulinism cases globally has increased the demand for effective treatment options to manage this rare genetic disorder.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Congenital hyperinsulinism treatment industry size was worth USD 146.4 million in 2022 and is estimated to witness 5.5% CAGR from 2023 to 2032 attributed to the increasing government initiatives to support the development and accessibility of treatments of rare genetic disorders.

The octreotide drug type segment is estimated to record 6.4% CAGR from 2023 to 2032 driven by the increasing use for providing effective symptom management for individuals with congenital hyperinsulinism.

North America congenital hyperinsulinism treatment market accounted for 61.3% revenue share in 2022 and is projected to expand at notable CAGR from 2023-2032 owing to the presence of advanced healthcare infrastructure, the strong focus on R&D and favorable regulatory environment.

Some major companies engaged in the congenital hyperinsulinism treatment industry are Crinetics Pharmaceuticals, Inc., Novartis AG, Zealand Pharma A/S, Rezolute, Inc., Hanmi Pharm.Co., Ltd, and Teva Pharmaceutical Industries Ltd, among others.